Punia Vps, Agrawal Nikhil, Bharti Akash, Mittal Shaavi, Chaudhary Dhirender, Mathur Atmika, Anwar Shahzad, Chakravorty Aditya
Internal Medicine, School of Medical Sciences and Research (SMSR) Sharda University, Greater Noida, IND.
Internal Medicine, University College of Medical Sciences, Delhi, IND.
Cureus. 2023 Jun 29;15(6):e41157. doi: 10.7759/cureus.41157. eCollection 2023 Jun.
Despite the extensive research conducted on the relationship between transforming growth factor-beta 1 (TGF-β1) polymorphisms and levels and the onset and development of liver disease, there are still certain gaps that need to be addressed. To address these gaps and provide a comprehensive overview of the current knowledge, this review aimed to identify relevant published research on TGF-β1/TGF-β1 polymorphism, TGF-β1/TGF-β1 levels, and their associations with cirrhosis and hepatitis C. The synthesis of available data was performed to further enhance our understanding in this area. Adopting the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, a search strategy was implemented across several online databases to search for relevant articles as per the defined selection criterion. Eight studies were selected after the completion of the search strategy. Of the eight studies, five revealed a considerably high level of TGF-β1 in patients who had hepatitis C virus (HCV) and liver cirrhosis caused by hepatocellular carcinoma (HCC). The forest plot analysis showed a statistically significant impact of TGF-β1 polymorphism and levels on the incidence of hepatic cirrhosis and hepatitis C, with an odds ratio (OR) of 0.65 and a risk ratio (RR) of 0.76. The heterogeneity test showed a high level of heterogeneity at 94% and 95% for OR and RR, respectively, but the overall effect was significant with < 0.01 for both measures. According to the results obtained, the authors concluded that TGF-β1 polymorphism and its associated levels should be taken into account while developing preventive and therapeutic approaches for hepatic cirrhosis and hepatitis C.
尽管针对转化生长因子β1（TGF-β1）多态性与水平以及肝病的发生和发展之间的关系进行了广泛研究，但仍存在一些需要解决的空白。为了填补这些空白并全面概述当前的知识，本综述旨在识别关于TGF-β1/TGF-β1多态性、TGF-β1/TGF-β1水平及其与肝硬化和丙型肝炎关联的相关已发表研究。对现有数据进行综合分析以进一步增进我们在该领域的理解。采用系统评价和Meta分析的首选报告项目（PRISMA）指南，在多个在线数据库中实施了搜索策略，以根据定义的选择标准搜索相关文章。搜索策略完成后，选取了八项研究。在这八项研究中，五项研究表明，丙型肝炎病毒（HCV）和由肝细胞癌（HCC）引起的肝硬化患者体内的TGF-β1水平相当高。森林图分析显示，TGF-β1多态性和水平对肝硬化和丙型肝炎的发病率有统计学上的显著影响，优势比（OR）为0.65，风险比（RR）为0.76。异质性检验显示，OR和RR的异质性水平分别为94%和95%，但两种测量方法的总体效应均显著，P值均<0.01。根据所得结果，作者得出结论，在制定肝硬化和丙型肝炎的预防和治疗方法时，应考虑TGF-β1多态性及其相关水平。
